Eli Lilly has revealed that subjects with moderately to severely active Crohn's disease have achieved long-term clinical and endoscopic outcomes after two years of continuous treatment with Omvoh ...

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...

The ad cost an estimated $2 million for the Secret Service to produce, according to two sources familiar with the project — a hefty price tag that comes amid massive budget cuts and layoffs at ...

Budweiser broke out the Clydesdales to win USA TODAY Ad Meter 2025, the ninth time the brand has claimed the prize as the Super Bowl's best commercial. The beer brand brought back the beloved ...

For the ninth time, Budweiser emerged as the winner of USA TODAY’s Ad Meter contest as viewers voted “First Delivery,” a tale of a Clydesdale foal proving its mettle, the No. 1 commercial in ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

In January the company announced that the US Food and Drug Administration had approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is the first ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ...

The Trump administration is preparing a new executive order that would seek thousands of layoffs at federal health agencies, including the FDA, according to the Wall Street Journal. Citing people ...